UnknownNot Applicable

A Long-term Follow-up Cohort Study in Patients With Intraductal Papillary Mucinous Neoplasm

1,500 participantsStarted 2022-12

Plain-language summary

Study objective: To establish a long-term follow-up cohort of patients with IPMN, study the follow-up, clinical outcomes and prognostic factors of patients with IPMN, and provide a basis for clinical decisions and guidelines. Study design: This is a real world, multicenter, prospective, observational cohort study

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age: 18 years old or above;
✓. Diagnosis: Imaging examination showed the presence of intraductal papillary mucinous cystic tumor (IPMN) without high-risk features (including WF and HRS);
✓. The patient or family members can understand the study protocol, are willing to participate in the study, and provide written informed consent.

Exclusion criteria

✕. The patient's clinical, imaging and auxiliary examination characteristics conform to the surgical indications of the International Association of Pancreatic Diseases (IAP) 2018 guidelines, and the patient has no surgical contraindication;
✕. Previous history of pancreatic malignant tumor;
✕. There were the following worrisome features (WF) of IPMN found in the past examination: acute pancreatitis, cyst size ≥ 30mm, cyst wall thickening/strengthening, main pancreatic duct diameter of 5-9.9mm, non enhanced mural nodules, sudden change of main pancreatic duct diameter with distal pancreatic atrophy;
✕. The following high risk features of IPMN (HRS) were found in the past: obstructive jaundice, enhanced mural nodules or related solid components, and main pancreatic duct\>10mm;
✕. The patient or family member could not understand the conditions and objectives of this study.

What they're measuring

The termination of the follow-up of IPMN patients, including death termination and recommended surgery termination.

Timeframe: 3 years

Trial details

NCT IDNCT05593393

SponsorPeking Union Medical College Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-09

Contact for this trial

Xi Wu, M.D.

13683296860 wxpumch@163.com

View on ClinicalTrials.gov More IPMN, Pancreatic trials